Power Law company profile

Kadmon

Biotech & Life Sciences · New York City, United States · Founded 2009 · IPO 2016 Unicorn

Developing therapies for immune disorders, fibrotic diseases and cancer

Valuation

$1.90B

Market cap · 2026

Revenue

$5.0M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Global footprint

Where Kadmon has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

230 monthly visits
across markets

🇺🇸 United States87%

Top 1 markets shown

Patent intelligence

$31M patent portfolio · 51 active families

Estimated portfolio value

$31M

1.6% of market cap · 5.3× smaller than top peer Amicus Therapeutics ($164M)

51 active patent families

Where Kadmon innovates PharmacologyMolecular biologyHost diseaseEndocrinologyDisease

Where Kadmon concentrates vs peers

Each axis is a top-10 topic across Kadmon and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Kadmon

An AI-synthesized read of the highest-engagement posts about Kadmon on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kadmon on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles